盐酸氨溴索治疗小儿支气管肺炎患儿的临床效果

Clinical effects of Ambroxol hydrochloride on children with bronchopneumonia

目的:观察盐酸氨溴索治疗小儿支气管肺炎患儿的临床效果。方法:选取90例小儿支气管肺炎患儿为研究对象,根据随机数字表法分为对照组和观察组各45例,对照组行常规治疗,观察组在对照组基础上联合盐酸氨溴索治疗,比较两组治疗有效率、临床症状消失时间、住院时间、治疗前后C反应蛋白(CRP)和白细胞计数(WBC)水平及不良反应发生率。结果:观察组治疗有效率为95.56%,高于对照组的75.56%,差异有统计学意义(P<0.05);观察组患儿咳痰、咳嗽、发热、呼吸困难、肺部湿啰音消失时间及住院时间均短于对照组,差异有统计学意义(P<0.05)。治疗前,两组患儿CRP和WBC水平比较,差异均无统计学意义(P>0.05);治疗后,两组患儿CRP和WBC水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为6.67%,与对照组的11.11%比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上采取盐酸氨溴索治疗小儿支气管肺炎患儿可提高治疗有效率,改善临床症状,以及降低CRP和WBC水平,其效果优于单纯常规治疗效果。

Objective: To analyze clinical effects of Ambroxol hydrochloride in treatment of children with bronchopneumonia. Methods: 90 children with bronchopneumonia were selected as the research objects, and were divided into control group and observation group by using the random number table method, 45 cases in each. The control group received routine treatment, while the observation group was treated with Ambroxol hydrochloride on the basis of that of the control group. The clinical effective rate, clinical symptom disappearance time, hospital stay, C-reactive protein(CRP) and white blood cell count(WBC) levels before and after the treatment, and incidence of adverse reactions were compared between the two groups. Results: The treatment effective rate in the observation group was 95.56%, which was higher than 75.56% in the control group, and the difference was statistically significant(P<0.05). The disappearance time of sputum, cough, fever, dyspnea and lung moist rales and hospital stay of the observation group were shorter than those of the control group, and the differences were statistically significant(P<0.05). Before the treatment, there were no significant differences in the CRP and WBC levels between the two groups(P>0.05). However, after the treatment, the CRP and WBC levels of the two groups were lower than those before the treatment;those of the observation group were lower than those of the control group;and the differences were statistically significant(P<0.05). Further, the incidence of adverse reactions in the observation group was 6.67%, compared with 11.11% in the control group, the difference was not statistically significant(P>0.05). Conclusions: On the basis of conventional treatment, Ambroxol hydrochloride in the treatment of the children with bronchopneumonia can improve the treatment effective rate, improve the clinical symptoms, and reduce the CRP and WBC levels. Moreover, it is superior to simple conventional treatment.